Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test

Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37665

Enrollment

100

Registered

2012-07-31

Start date

2012-11-30

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lithium-induced nephrogenic diabetes insipidus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: stable patients with a mood disorder treated with lithium men and women age >= 18 years

Exclusion criteria

Exclusion criteria: general contra-indications for participation in a trial: inability to give informed consent pregnancy unstable psychiatric condition;alternative causes of (nephrogenic) diabetes insipidus: hypo/hyperkalemia (plasma potassium 5.5 mmol/l) severe hypercalcemia (albumin-corrected plasma calcium > 2.80 mmol/l) hyperglycemia (plasma glucose > 10.0 mmol/l) history of amyloidosis, Sjögren*s syndrome or Sickle cell anemia previous treatment with ifosfamide established primary polydipsia or central diabetes insipidus;contra-indications for dDAVP administration: inability to comply with water restriction renal insufficiency (GFR

Design outcomes

Primary

Measure	Time frame
Maximal urinary osmolality after intranasal administration of dDAVP.	—

Secondary

Measure	Time frame
Relation of the dDAVP test results with complaints (micturition history) and clinical parameters (duration of lithium therapy, plasma lithium concentration, baseline plasma creatinine, sodium and potassium concentration and baseline urinary osmolality).	—

Countries

Netherlands

Outcome results